A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2001
10/23/2001	US6306863 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
10/23/2001	US6306854 Chemical compounds
10/23/2001	US6306840 Cell adhesion inhibitors
10/23/2001	US6306828 Enantiomerically-enhanced nutritional energy substrates
10/23/2001	US6306819 Method for regulating size of vascularized normal tissue
10/23/2001	US6306655 Antisense inhibition of C/EBP alpha expression
10/23/2001	US6306622 cDNA encoding a BMP type II receptor
10/23/2001	US6306432 High and low load formulations of IGF-I in multivesicular liposomes
10/23/2001	US6306430 Process for decreasing adiposity using vitamin a as a dietary supplement
10/23/2001	CA2236368C Sublingual and buccal administration of selegiline
10/23/2001	CA2108064C Thiazolidine dione compounds, process for preparing same and pharmaceutical compositions containing same
10/23/2001	CA2107150C Chromenic derivatives having a triene lateral chain, process for the preparation thereof and pharmaceutical compositions containing them
10/23/2001	CA2047496C Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
10/23/2001	CA2023404C Phosphorylated glycosidase inhibitor prodrugs
10/18/2001	WO2001077681A1 Tpst-assay for diagnosis of autism and related disorders
10/18/2001	WO2001077338A2 Human protein kinases and protein kinase-like enzymes
10/18/2001	WO2001077327A1 THE HIGH BONE MASS GENE OF 11q13.3
10/18/2001	WO2001077300A2 Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
10/18/2001	WO2001077174A2 Human transporters and ion channels
10/18/2001	WO2001077166A1 Novel physiologically active peptides and use thereof
10/18/2001	WO2001077146A2 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	WO2001077137A1 Albumin fusion proteins
10/18/2001	WO2001077136A1 Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
10/18/2001	WO2001077101A1 Chemical compounds
10/18/2001	WO2001077100A2 Benzoamide piperidine compounds as substance p antagonists
10/18/2001	WO2001077094A1 Percyquinnin, a process for its production and its use as a pharmaceutical
10/18/2001	WO2001077093A1 Estrogen agonist/antagonist metabolites
10/18/2001	WO2001077089A1 New neurokinin antagonists for use as medicaments
10/18/2001	WO2001077087A1 Novel compounds
10/18/2001	WO2001077085A1 Quinazoline compounds
10/18/2001	WO2001077073A1 Cathepsin cysteine protease inhibitors
10/18/2001	WO2001077072A2 Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
10/18/2001	WO2001077069A1 Naphthamide neurokinin antagonists for use as medicaments
10/18/2001	WO2001076715A2 Method for the fractionation of oil and polar lipid-containing native raw materials
10/18/2001	WO2001076584A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	WO2001076583A1 Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes
10/18/2001	WO2001076578A2 Treatment of icu-associated hypocalcemia with vitamin d compounds
10/18/2001	WO2001076574A2 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
10/18/2001	WO2001076573A2 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076568A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/18/2001	WO2001076394A1 Starch sub-types and lipid metabolism
10/18/2001	WO2001076385A1 Method for the fractionation of oil and polar lipid-containing native raw materials using alcohol and centrifugation
10/18/2001	WO2001076361A1 Animal and cell models for type ii diabetes and their use
10/18/2001	WO2001039724A3 Phosphonate compounds
10/18/2001	WO2001035933A3 A method of microencapsulation
10/18/2001	WO2001023388A3 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
10/18/2001	WO2000057837A9 Compositions and methods for effecting the levels of cholesterol
10/18/2001	WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage
10/18/2001	US20010032337 Introduction of exogenous nucleotide sequences into a genome by microinjection of infectious retrovirus into the perivitelline space of the egg; making a bovine embryo; use to confer disease resistance, for example
10/18/2001	US20010031857 Memno peptides, process for their preparation and use thereof
10/18/2001	US20010031786 Antidiabetic agents, obesity
10/18/2001	US20010031785 Orally administering zinc tranexamate for diabetis therapy
10/18/2001	US20010031782 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
10/18/2001	US20010031777 Heterocyclic compounds and their therapeutic use
10/18/2001	US20010031772 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals
10/18/2001	US20010031770 Pyridoxal analogues and methods of treatment
10/18/2001	US20010031767 Used as antidepressants, to treat obsessive compulsive disorder, panic disorders, bulimia, anorexia, pain, obesity, senile demential, migraines, and social phobias
10/18/2001	US20010031764 3-(4-(2-(5h-dibenzo(a,d)cyclohepten-5-yloxy)-ethoxyl-phenyl)-2 -ethoxy-propionic acid ethyl ester as antidiabetic agents and to treat obesity
10/18/2001	US20010031762 3-(4-(2-(5h-dibenzo(a,d)cyclohepten-5-yloxy)-ethoxyl-phenyl)-2 -ethoxy-propionic acid ethyl ester as antidiabetic agents and to treat obesity
10/18/2001	US20010031752 Administered as anorexigenic agents, dietetics, antidiabetics and for enhancing lipid metabolism
10/18/2001	US20010031741 Methods for treatment of lysosomal storage diseases
10/18/2001	US20010031740 Mixture containing organic halide
10/18/2001	US20010031726 Mixture of buffer, zinc, phenolic preservative and isotonic agent
10/18/2001	US20010031725 Polysaccharides
10/18/2001	US20010031265 Soaking in solution; then culturing
10/18/2001	US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders
10/18/2001	DE10013782A1 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln 4-fluoroalkyl-2H-benzopyrans with antiestrogenic action, processes for their preparation, pharmaceutical compositions containing them and their use for the preparation of medicaments
10/18/2001	CA2414652A1 Animal and cell models for type ii diabetes and their use
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405895A1 Combination of organic compounds
10/18/2001	CA2405870A1 Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
10/18/2001	CA2405793A1 Combination of organic compounds
10/18/2001	CA2405476A1 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	CA2405411A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	CA2405152A1 Treatment of icu-associated hypocalcemia with vitamin d compounds
10/18/2001	CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001	CA2405070A1 Estrogen agonist/antagonist metabolites
10/18/2001	CA2405066A1 Percyquinnin, a process for its production and its use as a pharmaceutical
10/18/2001	CA2405012A1 Starch sub-types and lipid metabolism
10/18/2001	CA2404971A1 Human protein kinases and protein kinase-like enzymes
10/18/2001	CA2404864A1 Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes
10/18/2001	CA2404630A1 Cathepsin cysteine protease inhibitors
10/18/2001	CA2404313A1 Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2404044A1 Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
10/18/2001	CA2403365A1 Quinazoline compounds
10/18/2001	CA2403012A1 Chemical compounds
10/18/2001	CA2402410A1 The high bone mass gene of 11q13.3
10/17/2001	EP1146125A1 Poxvirus with targeted infection specificity
10/17/2001	EP1146050A1 Remedies
10/17/2001	EP1146041A1 Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline
10/17/2001	EP1145718A1 DICARBA-closo-DODECABORANE DERIVATIVES
10/17/2001	EP1145717A2 Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor
10/17/2001	EP1145709A1 Use of natural products to prepare cosmetic compositions
10/17/2001	EP1144997A2 Methods and compounds for modulating nuclear receptor activity
10/17/2001	EP1144682A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
10/17/2001	EP1144673A1 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith
10/17/2001	EP1144648A1 Cyclic nucleotide-associated proteins
10/17/2001	EP1144631A2 Insulin-synthesis genes

1 ... 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 ... 1298